Menu
Join SOPHiA GENETICS at Pathology Update 2025 in Australia!
We are thrilled to announce our participation in the Pathology Update 2025, organized by the Royal College of Pathologists of Australasia (RCPA), for the very first time! This prestigious event will take place in Australia, showcasing the theme: 'Excellence in Diagnosis.'
Visit us at Booth #30 to discover how SOPHiA GENETICS is revolutionising the field of precision medicine. As clinicians and pathologists work tirelessly to achieve more accurate diagnoses and improve patient outcomes, we are here to support these efforts with our innovative, data-driven solutions.
Register to Pathology Update 2025 through here
SOPHiA GENETICS™ thrilled to be back at ASCO 2025! Meet our experts at booth #32131 to hear about our biopharma solutions.Learn how we are leveraging our unique AI expertise, to provide an unparalleled offering, unlocking insights from complex data types, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines
SOPHiA GENETICS™ thrilled to be back at AACR 2025! Visit us at booth #2856 to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions. By harnessing the power of AI and multimodal data-driven analytics, we enable you to advance and streamline global access to precision therapies.
Join us at ESMO 2025! Find out how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions.
We are excited to be back at ECP in 2025! Join us and explore more about our recent developments in Liquid Biopsy, CGP, Solid Tumors and more!
#PrecisionMedicine #RealWorldData #Genomics #DataDrivenMedicine #Oncology
SOPHiA GENETICS™ thrilled Charité Mayo Conference 2025! Visit us to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions.
SOPHiA GENETICS is excited to be a part of the Association for Molecular Pathology (AMP) 2024 Europe Congress held in Madrid, Spain from June 24th - 26th.
You will have the chance to chat with our experts at booth #12 and demo the universal SOPHiA DDM™ Platform.
Join us for our talk "From DNA to insights: Uncovering the overlooked with innovative NGS technology for MRD assessment" presented by Jose Maria Belloso, PhD, Global Product Manager – HemOnc, SOPHiA GENETICS and Silvia Salmoiraghi, PhD, Ultra-specialist Laboratory of Clinical Pathology-Hematology, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
During our presentation, the following topics will be discussed:
Date: June 25th, 2024
Time: 9:45 - 10:45
While on site, make sure to check out our poster:
Fine-Tuning Sensitivity: Establishing an Optimal Framework for Measurable Residual Disease Detection in Acute Myeloid Leukemia at 0.01%
R. Kempfer, J. Bieler, Y. Liu, A. Willig, S. Kubik, Z. Xu
We look forward to seeing you there!
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.